MedTrace Logo

Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma

NCT04673630 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-01-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.

Conditions

Interventions

BIOLOGICAL

Tezepelumab

Single dose subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Jonathan Grigg, MD · Royal London Hospital, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2022-09-27
Completion
2022-09-27
FDA Drug
Yes

Countries

  • Hungary
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673630 on ClinicalTrials.gov